U.S. markets close in 5 hours 53 minutes

Aethlon Medical, Inc. (AEMD)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.6502+0.1002 (+6.46%)
As of 10:06AM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Previous Close1.5500
Open1.6900
Bid1.6200 x 3100
Ask1.6200 x 1000
Day's Range1.6100 - 1.6900
52 Week Range0.7600 - 4.3400
Volume258,801
Avg. Volume547,855
Market Cap19.948M
Beta (5Y Monthly)0.31
PE Ratio (TTM)N/A
EPS (TTM)-0.7060
Earnings DateFeb 08, 2021 - Feb 12, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Aethlon Announces Appointment of Charles J. Fisher, Jr., M.D. as Chief Executive Officer
    PR Newswire

    Aethlon Announces Appointment of Charles J. Fisher, Jr., M.D. as Chief Executive Officer

    Aethlon Medical, Inc. (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening diseases, announced today the appointment of Charles J. Fisher, Jr., M.D., as Chief Executive Officer, effective as of October 30, 2020. Dr. Fisher joined Aethlon as a member of Aethlon's Board of Directors and has served as Chairman of the Board since November 2017. Mr. Ed Broenniman replaced Dr. Fisher as the Chairman of the Board effective as of October 30, 2020. Dr. Fisher brings an impressive record of results in global, strategic and operational roles to Aethlon. Dr. Fisher succeeds Dr. Timothy Rodell, who will serve as a consultant to Aethlon during the transition.

  • AEMD: Oncology EFS Open For Enrollment
    Zacks Small Cap Research

    AEMD: Oncology EFS Open For Enrollment

    By M. Marin NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT Aethlon Medical Inc. (NASDAQ:AEMD), a medical technology company engaged in developing products to diagnose and treat diseases in oncology and viral diseases that are life and organ threatening and not addressed with already approved treatments, reported 2Q FY 2021 results last night and provided a business update. The company’s lead

  • Aethlon Medical Announces Second Quarter Financial Results and Provides Corporate Update
    PR Newswire

    Aethlon Medical Announces Second Quarter Financial Results and Provides Corporate Update

    Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on developing products to diagnose and treat life and organ threatening diseases, today reported financial results for its second quarter ended September 30, 2020 and provided an update on recent developments.